{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:02:53Z","timestamp":1761541373877},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13014-017-0872-2","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T13:19:47Z","timestamp":1503062387000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial"],"prefix":"10.1186","volume":"12","author":[{"given":"Ping","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Krockenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Vonthein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Tereszczuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Liebau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Huttenlocher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Imhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Balermpas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Dellas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus-Peter","family":"J\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex S.","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Blanck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Dunst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,18]]},"reference":[{"issue":"6","key":"872_CR1","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374\u2013403.","journal-title":"Eur J Cancer"},{"key":"872_CR2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-5347(17)59889-4","volume":"111","author":"DF Gleason","year":"1974","unstructured":"Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111:58\u201364.","journal-title":"J Urol"},{"key":"872_CR3","first-page":"171","volume-title":"Tannenbaum M, ed","author":"DF Gleason","year":"1977","unstructured":"Gleason DF. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, ed. Urologic Pathology: The Prostate; 1977. p. 171\u201397."},{"key":"872_CR4","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.1997.03540420041027","volume":"277","author":"AW Partin","year":"1997","unstructured":"Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445\u201351.","journal-title":"JAMA"},{"key":"872_CR5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0090-4295(01)01441-8","volume":"58","author":"AW Partin","year":"2001","unstructured":"Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology. 2001;58:843\u20138.","journal-title":"Urology"},{"key":"872_CR6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1464-410X.2012.11045.x","volume":"109","author":"JJ Ischia","year":"2012","unstructured":"Ischia JJ, Pang CY, Tay YK, et al. Active surveillance for prostate cancer: an Australian experience. BJU Int. 2012;109:40\u20133.","journal-title":"BJU Int"},{"key":"872_CR7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM199401273300403","volume":"330","author":"GW Chodak","year":"1994","unstructured":"Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330:242\u20138.","journal-title":"N Engl J Med"},{"key":"872_CR8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1464-410X.1993.tb00690.x","volume":"72","author":"G Waaler","year":"1993","unstructured":"Waaler G, Stenwig AE. Prognosis of localised prostatic cancer managed by \u201cwatch and wait\u201d policy. Br J Urol. 1993;72:214\u20139.","journal-title":"Br J Urol"},{"key":"872_CR9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1113162","volume":"367","author":"TJ Wilt","year":"2012","unstructured":"Wilt TJ, Brawer MK, Jones KM, et al. Prostate cancer intervention versus observation trial (PIVOT) study group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203\u201313.","journal-title":"N Engl J Med"},{"key":"872_CR10","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1056\/NEJMoa043739","volume":"352","author":"A Bill-Axelson","year":"2005","unstructured":"Bill-Axelson A, Holmberg L, Ruutu M, et al. Scandinavian prostate cancer group study no. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977\u201384.","journal-title":"N Engl J Med"},{"issue":"11","key":"872_CR11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa012794","volume":"347","author":"L Holmberg","year":"2002","unstructured":"Holmberg L, Bill-Axelson A, Helgesen F, et al. Scandinavian prostatic cancer group study number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347(11):781\u20139.","journal-title":"N Engl J Med"},{"key":"872_CR12","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/jnci\/dji313","volume":"97","author":"SM Alibhai","year":"2005","unstructured":"Alibhai SM, Leach M, Tomlinson G, et al. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst. 2005;97:1525\u201332.","journal-title":"J Natl Cancer Inst"},{"key":"872_CR13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0022-5347(01)62924-0","volume":"160","author":"JT Bishoff","year":"1998","unstructured":"Bishoff JT, Motley G, Optenberg SA, et al. Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. J Urol. 1998;160:454\u20138.","journal-title":"J Urol"},{"key":"872_CR14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0022-5347(17)35645-8","volume":"150","author":"WJ Catalona","year":"1993","unstructured":"Catalona WJ, Basler JW. Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. J Urol. 1993;150:905\u20137.","journal-title":"J Urol"},{"key":"872_CR15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0140-6736(98)05180-0","volume":"353","author":"DP Dearnaley","year":"1999","unstructured":"Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet. 1999;353:267\u201372.","journal-title":"Lancet"},{"key":"872_CR16","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.juro.2008.07.038","volume":"180","author":"AM Nieder","year":"2008","unstructured":"Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol. 2008;180:2005\u20139.","journal-title":"J Urol"},{"key":"872_CR17","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","volume":"358","author":"MG Sanda","year":"2008","unstructured":"Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med. 2008;358:1250\u201361.","journal-title":"N Engl J Med"},{"key":"872_CR18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1209978","volume":"368","author":"MJ Resnick","year":"2013","unstructured":"Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436\u201345.","journal-title":"N Engl J Med"},{"key":"872_CR19","doi-asserted-by":"crossref","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al; ProtecT Study Group. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375(15):1415-1424.","DOI":"10.1056\/NEJMoa1606220"},{"issue":"7","key":"872_CR20","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/cncr.25467","volume":"17","author":"ZA Alicikus","year":"2011","unstructured":"Alicikus ZA, Yamada Y, Zhang Z, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2011;17(7):1429\u201337.","journal-title":"Cancer"},{"issue":"1","key":"872_CR21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijrobp.2011.11.047","volume":"84","author":"MJ Zelefsky","year":"2012","unstructured":"Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(1):125\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"872_CR22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ijrobp.2011.12.070","volume":"83","author":"J Michalski","year":"2012","unstructured":"Michalski J, Winter K, Roach M, et al. Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys. 2012;83(3):363\u201370.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"872_CR23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.eururo.2012.06.055","volume":"65","author":"BL Jacobs","year":"2014","unstructured":"Jacobs BL, Zhang Y, Skolarus TA, et al. Comparative effectiveness of external-beam radiation approaches for prostate cancer. Eur Urol. 2014;65(1):162\u20138.","journal-title":"Eur Urol"},{"key":"872_CR24","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","volume":"24","author":"ST Peeters","year":"2006","unstructured":"Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990\u20136.","journal-title":"J Clin Oncol"},{"key":"872_CR25","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","volume":"53","author":"A Pollack","year":"2002","unstructured":"Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097\u2013105.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"872_CR26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/02841860410002824","volume":"44","author":"JF Fowler","year":"2005","unstructured":"Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 2005;44(3):265\u201376.","journal-title":"Acta Oncol"},{"key":"872_CR27","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ijrobp.2009.12.045","volume":"79","author":"G Arcangeli","year":"2011","unstructured":"Arcangeli G, Fowler J, Gomellini S, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011;79:1013\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"872_CR28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijrobp.2010.10.075","volume":"82","author":"R Miralbell","year":"2012","unstructured":"Miralbell R, Roberts SA, Zubizarreta E, et al. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2 = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys. 2012;82(1):17\u201324.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"872_CR29","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/0284186X.2012.719635","volume":"51","author":"A Dasu","year":"2012","unstructured":"Dasu A, Toma-Dasu I. Prostate alpha\/beta revisited - an analysis of clinical results from 14168 patients. Acta Oncol. 2012;51(8):963\u201374.","journal-title":"Acta Oncol"},{"key":"872_CR30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(11)70293-5","volume":"13","author":"D Dearnaley","year":"2012","unstructured":"Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. 2012;13:43\u201354.","journal-title":"Lancet Oncol"},{"issue":"20","key":"872_CR31","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016 Jul 10;34(20):2325\u201332.","journal-title":"J Clin Oncol"},{"issue":"1","key":"872_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00066-016-1041-5","volume":"193","author":"S H\u00f6cht","year":"2017","unstructured":"H\u00f6cht S, Aebersold DM, Albrecht C, et al. Hypofractionated radiotherapy for localized prostate cancer. Strahlenther Onkol. 2017;193(1):1\u201312.","journal-title":"Strahlenther Onkol"},{"key":"872_CR33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1159\/000322507","volume":"43","author":"C King","year":"2011","unstructured":"King C. Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial. Front Radiat Ther Oncol. 2011;43:428\u201337.","journal-title":"Front Radiat Ther Oncol"},{"key":"872_CR34","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ijrobp.2008.05.059","volume":"73","author":"CR King","year":"2009","unstructured":"King CR, Brooks JD, Gill H, et al. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73:1043\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"872_CR35","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","volume":"82","author":"CR King","year":"2012","unstructured":"King CR, Brooks JD, Gill H, et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:877\u201382.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"872_CR36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1743-7563.2012.01589.x","volume":"10","author":"YH Lee","year":"2012","unstructured":"Lee YH, Son SH, Yoon SC, et al. Stereotactic body radiotherapy for prostate cancer: a preliminary report. Asia Pac J Clin Oncol. 2012;10(2):46\u201353.","journal-title":"Asia Pac J Clin Oncol"},{"key":"872_CR37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/COC.0b013e3181c4c7c4","volume":"34","author":"NC Townsend","year":"2011","unstructured":"Townsend NC, Huth BJ, Ding W, et al. Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol. 2011;34:6\u201310.","journal-title":"Am J Clin Oncol"},{"key":"872_CR38","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/cncr.26699","volume":"118","author":"SM McBride","year":"2012","unstructured":"McBride SM, Wong DS, Dombrowski JJ, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi- institutional phase 1 feasibility trial. Cancer. 2012;118:3681\u201390.","journal-title":"Cancer"},{"key":"872_CR39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-4-12","volume":"4","author":"EK Oermann","year":"2011","unstructured":"Oermann EK, Suy S, Hanscom HN, et al. Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. J Hematol Oncol. 2011;4:12.","journal-title":"J Hematol Oncol"},{"key":"872_CR40","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.canrad.2007.07.005","volume":"11","author":"JM Hannoun-Levi","year":"2007","unstructured":"Hannoun-Levi JM, Benezery K, Bondiau PY, et al. Robotic radiotherapy for prostate cancer with CyberKnife. Cancer Radiother. 2007;11:476\u201382.","journal-title":"Cancer Radiother"},{"key":"872_CR41","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ijrobp.2006.10.050","volume":"67","author":"BL Madsen","year":"2007","unstructured":"Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67:1099\u2013105.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"872_CR42","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.ijrobp.2007.11.067","volume":"70","author":"DB Fuller","year":"2008","unstructured":"Fuller DB, Naitoh J, Lee C, et al. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys. 2008;70:1588\u201397.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"872_CR43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1748-717X-6-3","volume":"6","author":"DE Freeman","year":"2011","unstructured":"Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol. 2011;6:3.","journal-title":"Radiat Oncol"},{"issue":"5","key":"872_CR44","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/153303461000900504","volume":"9","author":"AJ Katz","year":"2010","unstructured":"Katz AJ. CyberKnife radiosurgery for prostate cancer. Technol Cancer Res Treat. 2010;9(5):463\u201372.","journal-title":"Technol Cancer Res Treat"},{"key":"872_CR45","first-page":"49","volume":"1","author":"AJ Katz","year":"2011","unstructured":"Katz AJ, Santoro M, Ashley R, et al. Stereotactic body radiation therapy for low- and low-intermediate-risk prostate cancer: is there a dose effect? Front Oncol. 2011;1:49.","journal-title":"Front Oncol"},{"key":"872_CR46","doi-asserted-by":"crossref","unstructured":"Xie Y, Djajaputra D, King CR, et al. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2008:236\u201346.","DOI":"10.1016\/j.ijrobp.2008.04.051"},{"key":"872_CR47","first-page":"48","volume":"1","author":"S Lei","year":"2011","unstructured":"Lei S, Piel N, Oermann EK, et al. Six-dimensional correction of intra-fractional prostate motion with CyberKnife stereotactic body radiation therapy. Front Oncol. 2011;1:48.","journal-title":"Front Oncol"},{"issue":"7","key":"872_CR48","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00066-015-0822-6","volume":"191","author":"C Marino","year":"2015","unstructured":"Marino C, Villaggi E, Maggi G, et al. A feasibility dosimetric study on prostate cancer: are we ready for a multicenter clinical trial on SBRT? Strahlenther Onkol. 2015;191(7):573\u2013481.","journal-title":"Strahlenther Onkol"},{"issue":"7","key":"872_CR49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00066-016-0971-2","volume":"192","author":"M Rucinska","year":"2016","unstructured":"Rucinska M, Kieszkowska-Grudny A, Nawrocki S. SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer: toxicity and quality of life assessment. Strahlenther Onkol. 2016;192(7):449\u201357.","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"872_CR50","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00066-015-0919-y","volume":"192","author":"V Rudat","year":"2016","unstructured":"Rudat V, Nour A, Hammoud M, et al. Image-guided intensity-modulated radiotherapy of prostate cancer: analysis of interfractional errors and acute toxicity. Strahlenther Onkol. 2016;192(2):109\u201317.","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"872_CR51","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00066-014-0766-2","volume":"191","author":"NA Hoffmans-Holtzer","year":"2015","unstructured":"Hoffmans-Holtzer NA, Hoffmans D, Dahele M, et al. Roll and pitch set-up errors during volumetric modulated arc delivery: can adapting gantry and collimator angles compensate? Strahlenther Onkol. 2015;191(3):272\u201380.","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"872_CR52","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ijrobp.2016.09.049","volume":"96","author":"A Widmark","year":"2016","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, et al. Extreme Hypofractionation versus conventionally fractionated radiotherapy for intermediate risk prostate cancer: early toxicity results from the Scandinavian randomized phase III trial \u201cHYPO-RT-PC\u201d. Int J Radiat Oncol Biol Phys. 2016;96(5):938\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"872_CR53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","volume":"18","author":"RD Timmerman","year":"2008","unstructured":"Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008;18(4):215\u201322.","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"872_CR54","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1120\/jacmp.v12i2.3368","volume":"12","author":"J Grimm","year":"2011","unstructured":"Grimm J, LaCouture T, Croce R, et al. Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy. J Appl Clin Med Phys. 2011;12(2):3368.","journal-title":"J Appl Clin Med Phys"},{"key":"872_CR55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijrobp.2009.03.078","volume":"76","author":"JM Michalski","year":"2010","unstructured":"Michalski JM, Gay H, Jackson A, et al. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys. 2010;76:123\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"872_CR56","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijrobp.2009.02.090","volume":"76","author":"AN Viswanathan","year":"2010","unstructured":"Viswanathan AN, Yorke ED, Marks LB, et al. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys. 2010;76:116\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"872_CR57","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fonc.2016.00122","volume":"6","author":"MC Repka","year":"2016","unstructured":"Repka MC, Guleria S, Cyr RA, et al. Acute urinary morbidity following stereotactic body radiation therapy for prostate cancer with prophylactic alpha-adrenergic antagonist and urethral dose reduction. Front Oncol. 2016;6:122.","journal-title":"Front Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-017-0872-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T13:20:13Z","timestamp":1503062413000},"score":1,"resource":{"primary":{"URL":"http:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-017-0872-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,18]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1186\/s13014-017-0872-2","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,18]]},"article-number":"138"}}